William Blair analyst Ryan Daniels has reiterated their bullish stance on PHR stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Daniels has given his Buy rating due to a combination of factors including Phreesia’s strong financial performance and strategic initiatives. The company reported impressive third-quarter results, surpassing market expectations in both revenue and adjusted EBITDA. This performance was driven by better-than-expected operational efficiencies, which reflect positively on the company’s management and business model.
Additionally, Phreesia’s introduction of a new healthcare provider marketing program for pharmaceutical manufacturers is seen as a strategic move that could enhance its market offerings and drive higher returns on investment. The company’s recent acquisition of AccessOne and the subsequent updates to fiscal 2026 guidance also suggest a positive outlook, with anticipated growth in both revenue and adjusted EBITDA. These elements combined indicate a strong potential for future growth, justifying the Buy rating.
In another report released yesterday, Needham also reiterated a Buy rating on the stock with a $35.00 price target.